Dermaxon, in collaboration with researchers at the University of Texas Medical Branch, is studying the neuroprotective effects of a CYP26 inhibitor under a grant sponsored by the Craig H. Neilsen Foundation.
DermaXon is proud to collaborate with researchers at the University of Texas Medical Branch on a project sponsored by the Department of Defense.
DermaXon Partners with New York Based AI company VantAI For Two Drug Development Programs
DermaXon announces its partnership with VantAI, a Roivant Biosciences Vant company, for the rapid acceleration of two of its drug development programs. VantAI leads the computational drug discovery space with technology at the bleeding edge of machine learning and...
DermaXon will be presenting at BIO 2020, NIH Innovation Zone June 8 -12, 2020
Dermaxon receives grant from the National Institute of Neurological Disorders and Stroke
September 2019: DermaXon received a Phase 1 STTR Grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for pruritus. This award, titled “TOPICAL SELECTIVE T-TYPE BLOCKERS FOR...
DermaXon LLC awarded grant for continued development of DX308 drug candidate for the treatment of Ichthyosis
MiSSOULA, Montana, Nov. 20, 2018 – DermaXon was been awarded a research grant from The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to further research treatment options for Ichthyosis.
Characterization of CYP26B1-selective Inhibitor, DX314, as a Potential Therapeutic for Keratinization Disorders.
Background: Retinoid-based therapies are commonly used in the treatment of disorders of keratinization and other skin disorders but can result in non-specific effects and adverse reactions. Use of retinoic acid metabolism blocking agents (RAMBAs) such as DX308 may...